Shanghai, China

Hongyuan Ren

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Mabwell (Shanghai) Bioscience Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hongyuan Ren. Retrieved from https://idiyas.com/inventor/hongyuan-ren

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Hongyuan Ren

Introduction

Hongyuan Ren is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of bioscience, particularly in the development of innovative antibodies. His work is recognized for its potential applications in medical science.

Latest Patents

Hongyuan Ren holds a patent for an "Antibody Against Nectin-4 and Application Thereof." This patent highlights his expertise in creating targeted therapies that could have a substantial impact on treating various diseases.

Career Highlights

Ren is currently employed at Mabwell (Shanghai) Bioscience Co., Ltd., where he continues to push the boundaries of scientific research. His role at Mabwell allows him to collaborate with other talented professionals in the field.

Collaborations

Some of his notable coworkers include Jin Wang and Xiaohong Xu. Their combined efforts contribute to the innovative environment at Mabwell, fostering advancements in bioscience.

Conclusion

Hongyuan Ren's work exemplifies the spirit of innovation in the bioscience industry. His contributions, particularly in antibody development, are paving the way for future medical breakthroughs.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…